Business Context and Reporting Period
This Form 8-K is a current report filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on September 16, 2026. The filing addresses a corporate action approved by the Board of Directors following stockholder authorization granted at the 2025 annual meeting.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment rather than financial performance results.
Material Changes
The primary material change is the implementation of a reverse stock split of the Company's common stock at a ratio of one-for-fifteen (1:15). Key details include:
- Effective Date: September 28, 2026, at 12:01 a.m. Eastern Time.
- Trading: Shares will begin trading on a split-adjusted basis under the existing symbol "MTNB" on September 28, 2026.
- Share Conversion: Outstanding shares will be divided by 15. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive a proportional cash payment.
- Ownership: Percentage ownership and voting power will remain substantially unchanged, barring minor adjustments due to fractional share cash-outs.
- Listing Status: The Company notes there is no assurance that this action will enable it to maintain its listing on the NYSE American.
Guidance, Outlook, and Risks
Management Commentary: The Board exercised its discretion to set the split ratio within the previously authorized range of 1:2 to 1:199. The action was taken to comply with NYSE American guidance requiring ten calendar days' public notice.
Risks and Contingencies:
- Delisting Risk: The filing explicitly states there can be no assurance that the reverse stock split will enable the Company to maintain its listing on the NYSE American.
- Administrative: Stockholders holding paper certificates may need to contact the transfer agent, VStock Transfer, LLC, to receive new certificates, though electronic holders require no action.
Investor Verification Checklist
- Verify the new CUSIP number (576810 402) with your brokerage firm prior to the effective date.
- Confirm the exact number of shares held post-split, accounting for any cash payment received for fractional shares.
- Monitor the NYSE American listing status of MTNB following the effective date of September 28, 2026.
- Review the Company's subsequent filings for any updates regarding compliance with exchange listing standards.